BeyondSpring Gears Up for IPO

Print Email

BeyondSpring has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company did not list and pricing details in the filing, but the offering is valued up to $100 million, although this number is usually just a placeholder. The company intends to list its shares on the Nasdaq under the symbol BYSI.

The underwriters for this offering are Citigroup, Guggenheim Securities, FBR, China Renaissance and Trout Capital.

This is a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. The company is focused on advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia, a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer. Plinabulin has also entered the first of a number of planned Phase 1/2 clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab.

The company said in the filing:

We have a novel, highly scalable business model integrating clinical resources in the United States and China. We believe that our combined United States and China development strategy provides significant advantages including the ability to conduct trials in China, faster enrollment, lower costs, expedited approval process, and access to China’s fast growing cancer market. Our drug development capabilities are empowered by strong interest from clinical investigators in the United States as well as by our understanding of the pharmaceutical industry, clinical resources and regulatory system in China.

BeyondSpring intends to use the net proceeds from this offering to further develop its pipeline, as well as for working capital and general corporate purposes.